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Background: Adverse drug reactions are one of the most common causes of death in industrialized Western
countries. Nowadays, empirical data from clinical studies for the approval and monitoring of drugs and molecular
databases is available.
Methods: The integration of database information is a promising method for providing well-based knowledge
to avoid adverse drug reactions. This paper presents our web-based decision support system GraphSAW which
analyzes and evaluates drug interactions and side effects based on data from two commercial and two freely
available molecular databases. The system is able to analyze single and combined drug-drug interactions,
drug-molecule interactions as well as single and cumulative side effects. In addition, it allows exploring associative
networks of drugs, molecules, metabolic pathways, and diseases in an intuitive way. The molecular medication
analysis includes the capabilities of the upper features.
Results: A statistical evaluation of the integrated data and top 20 drugs concerning drug interactions and side
effects is performed. The results of the data analysis give an overview of all theoretically possible drug interactions
and side effects. The evaluation shows a mismatch between pharmaceutical and molecular databases. The
concordance of drug interactions was about 12% and 9% of drug side effects. An application case with prescribed
data of 11 patients is presented in order to demonstrate the functionality of the system under real conditions. For
each patient at least two interactions occured in every medication and about 8% of total diseases were possibly
induced by drug therapy.
Conclusions: GraphSAW (http://tunicata.techfak.uni-bielefeld.de/graphsaw/) is meant to be a web-based system for
health professionals and researchers. GraphSAW provides comprehensive drug-related knowledge and an improved
medication analysis which may support efforts to reduce the risk of medication errors and numerous drastic side effects.
Keywords: Medical informatics, Information system, Decision support system, Drug therapy, Adverse drug interaction,
Adverse drug reaction, Drug side effectsBackground
In recent decades the development of highly effective
drugs has crucially marked scientifically-based medicine.
According to recent studies every fifth medication is in-
correct and every fourteenth medication is potentially
dangerous [1]. Over ten years it has been known that 1%
of medication errors lead to adverse drug reactions* Correspondence: alshoshi@techfak.uni-bielefeld.de
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unless otherwise stated.(ADRs) [2,3] and are a common cause of death [4]. In
2001, a study by Ebbesen et al. [5] provided reliable data
on such deaths. They investigated 732 deaths among
13,992 patients over a treatment period of two years
with regard to the cause of death and showed that 0.95%
of patients in a department of internal medicine suffered
fatal adverse drug events (ADEs). Autopsy results and
postmortem blood level measurements used for identify-
ing the exact cause of death showed for the first time
that almost half of these deaths were due to avoidable
drug-drug interactions and dosage errors [5]. In case ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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thousands of deaths per year as a consequence of medi-
cation errors [6].
Computerized physician order entry systems (CPOES)
and computerized decision support systems (CDSS) as-
sist in the prescription of drugs and indicate potentially
serious drug interactions as well as overdoses [7,8]. The
risk check of available patient data and their respective
drugs is based on pharmaceutical databases. Several
interaction databases, including ABDA [9], MediQ [10],
DrugDex [11] and AiDKlinik® [12], were evaluated by
the hospital Klinikum Dachau with regard to the retrieval
rate and relevance of drug interactions. A practical test
[13] showed that all theoretically possible drug interac-
tions described in literature cannot be found within only
one database. For a reliable retrieval it is necessary to
check drug interactions by using at least two databases.
In the recent past a variety of commercial and non-
commercial drug-related databases have been estab-
lished. Despite the large amount of drug-related infor-
mation, the optimization of multi-medications using
additional molecular data remains still complicated.
These databases can however help to identify uncovered
patient risk factors in the patient-specific drug therapy
and to exclude certain drugs for patient treatment (e.g.,
if there is a serious drug-drug interaction or if the
patient's metabolic profile does not respond to a specific
drug).
Appropriate systems for health professionals and re-
searchers are required to achieve substantial improve-
ments in drug prescription quality for above reasons.
For this purpose we have developed a web-based sys-
tem named GraphSAW which integrates drug-related
pharmaceutical and molecular databases. This combin-
ation enables GraphSAW to provide a discovery toolkit
for analysis and visualization of drug interactions and
side effects.
Related work
To meet the challenges of drug therapy safety, we evalu-
ated three related web-based systems to expose their ad-
vantages and disadvantages.
Promiscuous
Promiscuous [14] was developed to facilitate the progress
of drug repositioning. The system includes three different
entities: drugs, proteins, and side effects. Information
about the relations of these entities was gathered from
different molecular databases. Additional information
was extracted and manually curated from PubMed
publications. All data was integrated into the independent
Promiscuous database. The system provides search forms
for drug-protein interactions, drug side effects, and
drug-pathway interactions. The results are shown in aninteractive network and listed in a tabular form. Note
that, there is no possibility for determining drug-drug
interactions.
Stitch
The search tool for interactions of chemicals, short
STITCH [15], is a database of interaction data and an
interactive web tool for the exploration of interaction
networks of proteins and chemicals, including drugs.
The basis of this system consists of chemical compounds
from PubChem which were mapped on thirteen molecu-
lar databases. In addition, a confidence-value is assigned
to each interaction relation based on the reliability of
the data source. The results are visualized in an inter-
active network with three different views: confident-
view, evidence-view, and action-view. Further informa-
tion of the network is shown in a table. Information
about metabolic pathways and drug side effects are not
included in STITCH.
Kegg medicus
KEGG MEDICUS [16] is an integrated information re-
source of diseases, drugs, and health-related substances,
aiming to bring the genomic revolution of society.
KEGG MEDICUS currently integrates the KEGG DRUG
and KEGG DISEASE databases, human pathways and
drug development pathways in KEGG PATHWAY data-
base, and FDA drug labels for both prescription and
OTC drugs in the USA and Japan. Given a list of drugs,
the Drug Interaction Checker reports any drug-drug inter-
actions associated with contraindications and precautions.
The information is computerized in lists. Network-based
information and visualization about drug side effects and
drug-induced diseases is missing.
As a concluding remark, the evaluation showed that
all presented systems were inappropriate for analyzing
multi-medications and avoiding adverse drug reactions.
They provided only functionalities either for drug-drug
interactions or drug side effects. Furthermore, the sys-
tems were using only molecular drug-related databases.
A commercial, pharmaceutical database such as ABDA,
which contains approved and validated drug-related
data, can ensure better data quality and more compre-
hensive knowledge. Moreover, an interaction network
can simplify the understanding of drug effects in the hu-
man organism. Because of these facts, a new system was
required. This new system should offer functionalities
for analyzing drug side effects and drug interactions at
different pharmaceutical and molecular levels. It should
offer insight into underlying biochemical networks where
drugs and molecules interact in the same metabolic path-
way. Therefore, the system should offer an associative
network and a tabular view in order to visualize the coher-
ency of results in an intuitive way.
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GraphSAW was developed as a user-friendly decision
support system for health professionals and re-
searchers and is based on common client/server archi-
tecture (Figure 1). It is a web-based system that is
platform independent and accessible via the Internet.
The application logic was implemented in PHP, a HTML,
b and CSS c. The core of GraphSAW represents the data-
base, which integrates drug-related pharmaceutical and
molecular databases. Due to this comprehensive know-
ledge GraphSAW provides a discovery toolkit for analysis
and visualization. JavaScript components for associative
network visualization were developed for a scientific yet
intuitive way of analyzing and exploring the data. There-
fore, jQuery and Information Visualization Toolkit library
(InfoVis) [17] were used.
An arbitrary set of user inputs are sent via an asyn-
chronous HTTP-request to the web server. On the ser-
ver side, the results of the database evaluation are
converted with PHP scripts into JSON format and trans-
ferred to the InfoVis library which renders the graph for
visualizing the results.
Data integration
GraphSAW contains six different types of entities: drugs,
interactions, side effects, molecules, diseases, and path-
ways. The entities are connected to each other throughFigure 1 Client/Server architecture of the system GraphSAW. The clien
data warehouse BioDWH. On the server side, an Apache HTTP Web server
The integrated databases are listed in the BioDWH.drug-drug interaction, drug-side effects, drug-molecule,
drug-disease, drug-pathway, and pathway-disease rela-
tions. To provide a comprehensive dataset, the informa-
tion was retrieved from two commercial and two freely
available databases: ABDA [9], KEGG [18], SIDER [19],
and DrugBank [20], whereas the latter represents the
basis of the system. DrugBank is the largest resource
that collects binding data on small molecules, in particu-
lar those of drugs and proteins. A total number of 6711
approved and experimental drugs were extracted and
mapped to additional databases. Moreover, DrugBank
contains drug-drug interactions as well as drug-protein
interactions combined with the DrugBank Partners data-
base. Further drug interactions were obtained from the
commercial database ABDA that is based on approved
and validated drug-related data in comparison to Drug-
Bank. ABDA contains comprehensive facts for dealing
with more than 47,000 drugs such as information about
application and composition, risks and drug interactions.
Codes of ATC [21], an Anatomical Therapeutical Chem-
ical classification system, were used to classify drugs of
the databases DrugBank and ABDA. These DrugBank
drugs were assigned to the ABDA drugs by ATC-codes
and identifiers. The ABDA database includes also the
side effects of drugs. More than 4500 side effects (3,135
different; 1,381 synonyms) were extracted automatically
from full-text information in German and translatedt communicates via Internet with a central server and the biological
and PHP scripts to dynamically generated static HTML pages are used.
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side effects were obtained from SIDER. Terms of
MedDRA d [22], a unified and standardized medical
terminology, were used for coding drug side effects of
both databases. The mapping between drugs of Drug-
Bank and SIDER was realized by drug names because
these databases did not have corresponding identifiers
for substances. By drug mapping, the interactions and
side effects were assigned to drugs of all databases.
Information about metabolic pathways was obtained
from KEGG, which already integrates substances from
DrugBank [20], PubChem [23], CAS [24], LigandBox
[25], and NIKKAJI [26]. DrugBank identifiers were used
for the mapping and merging of these data sources.
All databases were integrated by implementing
SAX e -Parser in Java and the bio data warehouse
BioDWH [27]. BioDWH is a novel bioinformatics
data warehouse software kit that integrates biological
information from multiple public life science data sources
into a local database management system. It differs from
other approaches by providing up-to-date integrated
knowledge, platform and database independence as well
as high usability and customization. This way of integra-
tion provides the transformation from different data file
types such as XML or TSV into MySQL databases. Using
the data warehouse architecture also ensures both the
availability as well as the relevance of the data sources.
An additional GraphSAW database was created to
store meta data such as extracted and translated side
effects from ABDA. It also contains lists of drugs for a
“so-called” auto-complete functionality. This feature is
used to suggest possible drugs to users, which guarantee
search results.
Data analysis and visualization
The user interface represents database entities (drugs,
side effects, molecules, diseases, and pathways) as nodes
in a network with edges representing the relations
between them. Starting from an arbitrary set of user in-
puts, the system analyzes the integrated knowledge and
makes an evaluation in terms of risks (Figure 2). The li-
brary generates a radial network, thus, one or a couple
of central nodes represent the inputs encircled by color-
coded results at higher levels (1). The radial network is
used to separate the results at different levels depending
on different databases. Detailed information about nodes
and edges are available as a color-coded plain list via the
bar on the right side (2). Furthermore, user inputs in the
search form (a) and basic graph settings (b) can be ad-
justed in the navigation bar (3) on the left side.
The data delivered by GraphSAW can be queried
through various search forms which are described in
more detail in the following. GraphSAW provides three
types of drug analysis: drug interactions and drug sideeffects, which are based on pharmaceutical and molecu-
lar data, and the molecular medication analysis which is
based on molecular data.
Analysis of drug interactions
Multi-medications are associated with a significantly
increased risk for adverse drug reactions and presents
health professionals with a major challenge of adequate
prescription. Drug interactions can be determined at
three different levels: drug-drug, drug-molecule, and
drug-pathway interactions.
At the first level, search forms for single and combined
drug interactions were implemented in GraphSAW.
‘Single drug interactions’ enables users to search for
interaction partners of a single drug. Interaction partners
are merged, compared, ordered alphabetical and visual-
ized depending on the databases ABDA and DrugBank.
’Combined drug interactions’ is one of the main features
of the system. This feature allows users to check their
multi-medications for interactions. Both pharmaceutical
and molecular drug-drug interactions are retrieved from
ABDA and DrugBank. Interacting drugs are placed as
color-coded nodes in the network with edges represent-
ing the interactions between them.
Drug-molecule interactions can be queried at the second
level. Especially the family of Cytochrome P450 Enzymes
(CYPs) plays an important role in the degradation of most
drugs. Many drugs inhibit or induce the activity of Cyto-
chrome P450 Enzymes (CYPs) which is important to
health professionals trying to give an appropriate dosage
of those drugs. If a drug induces a CYP that is also active
in another drug’s metabolism, the dosage of the first drug
must be enhanced to achieve a therapeutic effect. In the
case of the inhibition of a CYP, the dosage of the drug can
be reduced which also decreases side effects. Interactions
between drugs and molecules (targets, enzymes, trans-
porter, and carrier proteins) can be queried by drug name.
This information is retrieved from DrugBank and Drug-
Bank Partners.
At the last level, drug-pathway and pathway-disease
networks can also be explored by GraphSAW. This drug
mapping on metabolic pathways or vice versa was im-
plemented in order to put the entities in a biochem-
ical context. This information is retrieved from KEGG
(DrugBank, PubChem, CAS, LigandBox, and NIKKAJI).
Drugs of a chosen database are mapped and visualized
on an entered metabolic pathway. Moreover, the total
number of result hits and matching results of the
remaining databases are shown in the side bar. The
effects of drugs can only be fully understood by consid-
ering a pathway-disease network, which includes drugs,
metabolic pathways, and diseases. The metabolic
network maps are probably the most comprehensive
of all biological networks. The easiest way to search
Figure 2 Network visualization interface of GraphSAW explaining „Single drug interactions“ for “Clonazepam”. The library
generates a radial network, thus, a central drug node encircled by color-coded interacting drugs at higher levels (1). On the first circle,
correlating interactions from ABDA and SIDER are placed and colored in green. On the second circle, drug-drug interactions from ABDA
(red), and on the last circle, drug-drug interactions from SIDER (yellow) are shown. Detailed information about nodes and edges are
available via the bar on the right side (2). Furthermore, user inputs in the search form (a) and basic graph settings (b) can be adjusted
in the navigation bar (3) on the left side.
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a pathway.
Analysis of drug side effects
Knowledge about drug side effects can be extremely use-
ful in supporting the quality of prescribing medications.
Similar to drug interactions, search forms for single and
cumulative drug side effects were implemented. ‘Single
drug side effects’ enables users to search for side effects
of a single drug. Package inserts of prescription drugs
(ABDA) are supposed to contain side effects but such
information is not necessarily complete. Therefore, the
side effects are merged, compared, ordered alphabetical
and visualized depending on the databases ABDA and
SIDER. Cumulative drug side effects are side effects that
occur in at least two of the prescribed drugs. This means
that the occurrence probability of cumulative side effects
increases with the number of prescribed drugs. There-
fore, they represent a particularly high risk – especially
for long-term treatments with psychotropic drugs. With
this feature, cumulative side effects of entered drugs can
be identified and avoided.
Molecular medication analysis
The ‘molecular medication analysis’ includes the previ-
ously mentioned search forms ‘combined drug interac-
tions’, ‘drug-molecule interactions’, and ‘drug side effects’.
This main feature allows users to check the medications
for molecular drug side effects, drug-drug and drug-
enzyme interactions. Therefore, users only need to enterthe prescribed drugs, occurred side effects or drug-induced
diseases, and the defect Cytochrome P450 enzymes (CYP)
into the system. As an example, Figure 3 shows the result
of the molecular medication analysis for seven drugs and
two side effects. Starting from this arbitrary set of user
inputs, the system checks whether a drug interacts with
another drug or causes side effects. Further information
like the effect of the interaction between two drugs, the
frequency of a side effect, and the activity of the defect
CYP can be queried.
Statistical evaluation and application case
The variety of possible drug interactions and side ef-
fects are not tallied systematically and are hardly man-
ageable, even for experts. GraphSAW gives insight into
the distribution of the integrated pharmaceutical and
molecular data concerning drug interactions and drug
side effects. Furthermore, an analysis of leading drugs
(top 20) was carried out, i.e., according to the number
of prescriptions made in 2008, in terms of drug inter-
actions and side effects. This data was obtained from
the “GEK-Arzneimittel-Report 2009” [28]. This report
of the German health insurance GEK evaluates the re-
sults of drug data in the period from 2007 to 2008. The
drug prescriptions include output drugs in pharmacies
paid by the GEK. Finally, an application case with real
life patient data was performed in order to analyze
multi-medications for drug interactions and drug-
induced diseases. The patient data was provided by a
medical practice.
Figure 3 Network visualization interface of GraphSAW explaining “molecular medication analysis” for seven drugs and two side
effects. The main window enables users to view the network of drug-drug interactions (red), drug-enzyme interactions (violet), drug side effects
(yellow), and drugs without potential risks (blue). The right side bar shows context sensitive information about nodes and edges.
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The distribution of drug interactions and drug side effects
data within the integrated pharmaceutical and molecular
databases was analyzed. As summarized in Figure 4, the
analysis has revealed a total of 51,520 drug interaction
hits, whereas 29,854 (58%) of the total interactions are re-
corded in ABDA and 15,518 (30%) in DrugBank. Further-
more, only 6,148 (12%) of total interactions are shared by
both databases. As a consequence, about 30% of total drug
interactions are missing in computerized decision support
systems which are based on pharmaceutical data of the
ABDA database.
The analysis of drug side effects has revealed an even
more surprising result. The number of total side effect
hits is 140,651 whereas 42,213 (30%) of the total sideFigure 4 Data distribution of drug interactions and side effects. Numb
and molecular data.effects are recorded in ABDA and 85,873 (61%) in
SIDER. The number of correlative side effect hits is
12,565 (9%). As a consequence, more than 60% of total
side effects are missing in ABDA. Similar to drug-drug
interactions only a small part of side effects are shared
by both databases.
Statistical evaluation of drug interactions
Figure 5 describes the number of identified drug interac-
tions of the top 20 drugs. The current analysis has re-
vealed a total of 1,567 interaction hits whereas 1,392
(88.83%) of the total interactions are recorded in ABDA
and 396 (25.27%) in DrugBank. The number of correla-
tive interaction hits is 221 (14.10%), representing the
overlap of both databases, while 1,346 hits (85.90%) areer of drug interactions and side effects retrieved from pharmaceutical
Figure 5 Number of drug interactions. Number of drug interactions retrieved from the databases ABDA and DrugBank in correlation to the
top 20 drugs.
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1,788 interaction hits recorded from both databases are
not matched with each other.
Statistical evaluation of drug side effects
Figure 6 shows the number of identified side effects of the
top 20 drugs. The number of total side effect hits is 3,890
whereas 1,444 (37.12%) of the total side effects are re-
corded in ABDA and 2,887 (74.22%) in DrugBank. The
number of correlative interaction hits is 441 (11.34%) and
3,449 hits (88.66%) are non-correlative. As a consequence,
it was revealed that 79.64% of the overall 4.331 side effect
hits from both databases are not matched with each other.
Application case
The following application case with real life data of
eleven patients demonstrates the GraphSAW system
under real conditions. The data was collected and pro-
vided by a medical practice. The patient’s data was col-
lected from 10 men and 1 woman with an average age of
78 years and an average weight of 87 kg. These patients
were diagnosed with 8 to 18 diseases and were treated
with 5 to 17 multiple drugs.The analysis of drug-drug interactions showed that at
least two interactions occured in every medication of
each patient. This bears a high potential for the occur-
rence of adverse drug reactions. Figure 7 shows the
number of medicinal products, drugs (active agents),
and drug interactions for each patient.
Even more important is the prevention of diseases
which can be induced by drug therapy. The occurrence
probability of these drug-induced diseases increases with
the number of drugs sharing the same side effects. As
summarized in Figure 8, 8.43% of total diseases were
possibly induced by drug therapy. 70% of these drug-
induced diseases occured only at more than one drug.
This result leads one to assume that the number of dis-
eases for each patient can be reduced by prescribing
fewer drugs.
The datasets of the patients and all results of the ana-
lyses are available at http://tunicata.techfak.uni-bielefeld.
de/graphsaw/application_case/index.html
Results
The statistical evaluation of data distribution showed a
mismatch between pharmaceutical and molecular
Figure 6 Number of drug side effects. Number of drug side effects retrieved from the databases ABDA and SIDER in correlation to the top
20 drugs.
Figure 7 Number of medicinal products, drugs, and interactions. Number of medicinal products, drugs (active agents), and interactions for
each patient.
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Figure 8 Number of drug-induced diseases. Number of all diseases, drug-induced and cumulative drug-induced diseases for each patient.
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about 12% and 9% of drug side effects. More than 30%
of the molecular drug interactions and more than 61%
of the molecular side effects were missing in the
pharmaceutical database. Therefore, they are also miss-
ing in most computerized decision support systems.
These results were confirmed by the analysis of the top
20 drugs on the German market. The concordance of
drug interactions was about 14% and 11% of drug side
effects. In addition, more than 35% of the molecular in-
teractions and more than 60% of the molecular side ef-
fects were not recorded in the pharmaceutical database.
Finally, the application case showed that for each patient
at least two interactions occured in every medication.
Moreover, about 8% of total diseases were possibly in-
duced by drug therapy.
Discussion
Although drugs are essential for the prevention and
proper treatment of diseases, multi-medications still may
cause serious adverse drug reactions which are usually
known. Reliability on the extent and quality of informa-
tion used by medical doctors for decision making lies at
the heart of efforts towards improving prescription qual-
ity. GraphSAW provides users a graphical view on a
well-based knowledge to analyze drug cocktails for
adverse drug reactions and drug-induced diseases. The
obtained results can be used to compare the risk of
disease against the therapeutic risk (benefit/risk rela-
tion), i.e., to avoid the risk of under-treatment of pa-
tients which is possibly an even greater risk. GraphSAW
will be extended by visualizing additional information
such as interaction profiles (mechanism, effect, etc.) or
side effect profiles (extent, frequencies, etc.). As adversedrug reactions do not occur in each patient in the same
extent due to inter-individual genetic differences, a new
feature to analyze polymorphisms is planned to be
implemented.
Conclusions
The drugs risks-check of decision support systems is
usually based on pharmaceutical databases. Despite the
large amount of drug-related information, the analysis
and optimization of multi-medications using additional
molecular data is still complicated and even for experts
unmanageable. With GraphSAW we presented a new
decision support system which integrates pharmaceutical
and molecular databases. Based on this comprehensive
knowledge, GraphSAW provides a toolkit for analysis
and visualization. Users can check their medications for
single and combined drug interactions, drug-molecule
interactions as well as single and cumulative side effects.
Moreover, the implemented visualization toolkit allows
exploring associative networks of drugs, molecules,
metabolic pathways, and diseases to fully understand ef-
fects of drugs in an intuitive way. Along this line the
dosage of drugs can be adjusted to the protein balance
of the patient, resulting in better drug tolerability. For
further support, the molecular medication analysis
includes the features of combined drug interactions,
drug-molecule interactions, and drug side effects at the
molecular level.
In conclusion, substantial improvements in patient
safety can be achieved by using GraphSAW which ana-
lyzes multi-medications and evaluates with regards to
pharmaceutical and molecular adverse drug reactions.
Potential drug interactions, drug side effects, and drug-
induced diseases can be avoided. Health professionals
Shoshi et al. BMC Medical Informatics and Decision Making  (2015) 15:15 Page 10 of 10and researchers gain more comprehensive knowledge
and can contribute to a patient-related analysis of medi-





dMedical Dictionary for Regulatory Activities.
eSAX is the Simple API for XML. SAX was the first
widely adopted API for XML in Java.
Availability and requirements
GraphSAW is available at http://tunicata.techfak.uni-
bielefeld.de/graphsaw/. Access to the system is restricted
by the commercial databases and will be enabled by a re-
quest to the authors. To access all features of the system,
the latest browser versions such as Internet Explorer 9+
or Mozilla Firefox 23+ should first be installed.
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